Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leeza Osipenko

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
BMJ Open|October 7, 2021
Audit of data redaction practices in NICE technology appraisals from 1999 to 2019Leeza Osipenko
Autoimmunity Reviews|September 11, 2003
General network of natural autoantibodies as immunological homunculus (Immunculus)Alexander Poletaev, Leeza Osipenko
BMC Pregnancy and Childbirth|January 20, 2011
A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and WalesAla Szczepura, Leeza Osipenko, Karoline Freeman
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 17, 2008
Non-invasive fetal RHD genotyping tests: a systematic review of the quality of reporting of diagnostic accuracy in published studiesKaroline Freeman, Ala Szczepura, Leeza Osipenko
BMJ Oncology|February 19, 2026
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitorsEmily S Zhang, Leeza Osipenko, John A Hickman
European Journal of Clinical Pharmacology|December 13, 2016
Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific adviceFrançois Maignen, Leeza Osipenko, Pilar Pinilla-Dominguez, et al.
International Journal of Technology Assessment in Health Care|July 9, 2020
NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstancesPilar Pinilla-Dominguez, Huseyin Naci, Leeza Osipenko, et al.
JAMA Network Open|July 28, 2023
Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor InhibitorsValerie Jentzsch, Leeza Osipenko, Jack W Scannell, et al.
Applied Health Economics and Health Policy|October 28, 2018
Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies GuidanceFrancisca Crispi, Huseyin Naci, Eva Barkauskaite, et al.
Journal of Clinical Epidemiology|September 22, 2018
A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectivenessMichael Anderson, Huseyin Naci, Deborah Morrison, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
BMJ Open|October 7, 2021
Audit of data redaction practices in NICE technology appraisals from 1999 to 2019Leeza Osipenko
Autoimmunity Reviews|September 11, 2003
General network of natural autoantibodies as immunological homunculus (Immunculus)Alexander Poletaev, Leeza Osipenko
BMC Pregnancy and Childbirth|January 20, 2011
A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and WalesAla Szczepura, Leeza Osipenko, Karoline Freeman
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 17, 2008
Non-invasive fetal RHD genotyping tests: a systematic review of the quality of reporting of diagnostic accuracy in published studiesKaroline Freeman, Ala Szczepura, Leeza Osipenko
BMJ Oncology|February 19, 2026
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitorsEmily S Zhang, Leeza Osipenko, John A Hickman
European Journal of Clinical Pharmacology|December 13, 2016
Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific adviceFrançois Maignen, Leeza Osipenko, Pilar Pinilla-Dominguez, et al.
International Journal of Technology Assessment in Health Care|July 9, 2020
NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstancesPilar Pinilla-Dominguez, Huseyin Naci, Leeza Osipenko, et al.
JAMA Network Open|July 28, 2023
Costs and Causes of Oncology Drug Attrition With the Example of Insulin-Like Growth Factor-1 Receptor InhibitorsValerie Jentzsch, Leeza Osipenko, Jack W Scannell, et al.
Applied Health Economics and Health Policy|October 28, 2018
Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies GuidanceFrancisca Crispi, Huseyin Naci, Eva Barkauskaite, et al.
Journal of Clinical Epidemiology|September 22, 2018
A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectivenessMichael Anderson, Huseyin Naci, Deborah Morrison, et al.
Pageof 2